{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["cabazitaxel"]],"indication":"docetaxel-treated metastatic castration-resistant prostate cancer in older men","name":"CABASTY","nct_id":"NCT02961257","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cabasty-nct02961257. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CABASTY","arms":[{"description":"Cabazitaxel 25 mg/m² intravenously over 1 hour on Day 1of a 3-week cycle, plus prednisone (or prednisolone) 10 mg orally given daily for a maximum of 10 cycles (ie 30 weeks of treatment).\n\nProphylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel.","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Cabazitaxel 16 mg/m2 on Day 1 and Day 15 of a 4-week cycle plus prednisone (or prednisolone) 10 mg per day up to 10 cycles (ie 40 weeks of treatment). Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel.","label":"Arm B","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2021-12-02","type":"ACTUAL"},"conditions":["Prostate Cancer Metastatic"],"enrollment":{"count":196,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"cabazitaxel","otherNames":["Jevtana","XRP6258"],"type":"DRUG"},{"name":"Prednisone","otherNames":[],"type":"DRUG"},{"name":"Granulocyte colony-stimulating factor (G-CSF)","otherNames":["Granocyte"],"type":"DRUG"}],"last_update":"2022-05-12","lead_sponsor":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","official_title":"Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 65years) With mCRPC Previously Treated With a Docetaxel-containing Regimen","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2021-12-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of grade ≥ 3 neutropenia and/or neutropenic complications","timeFrame":"Up to 11 months"}],"references":[{"citation":"Vauchier C, Thibault C, Velev M, Becker O, Guillaume Z, Ashton E, Zaibet S, Berthou H, Courtinat F, Gervais C, Rochand A, Robbrecht D, Oudard S, Auclin E. Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials. Eur Urol Oncol. 2026 Apr 21:S2588-9311(26)00081-7. doi: 10.1016/j.euo.2026.03.022. Online ahead of print.","pmid":"42020286","type":"DERIVED"},{"citation":"Oudard S, Ratta R, Voog E, Barthelemy P, Thiery-Vuillemin A, Bennamoun M, Hasbini A, Aldabbagh K, Saldana C, Sevin E, Amela E, Von Amsberg G, Houede N, Besson D, Feyerabend S, Boegemann M, Pfister D, Schostak M, Huillard O, Di Fiore F, Quivy A, Lange C, Phan L, Belhouari H, Tran Y, Kotti S, Helissey C. Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023 Dec 1;9(12):1629-1638. doi: 10.1001/jamaoncol.2023.4255.","pmid":"37883073","type":"DERIVED"},{"citation":"Pobel C, Auclin E, Procureur A, Clement-Zhao A, Simonaggio A, Delanoy N, Vano YA, Thibault C, Oudard S. Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review. Future Oncol. 2021 Jan;17(1):91-102. doi: 10.2217/fon-2020-0672. Epub 2020 Dec 2.","pmid":"33463373","type":"DERIVED"}],"start_date":{"date":"2017-05-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel","url":"https://clinicaltrials.gov/study/NCT02961257"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cabasty-nct02961257"}